Table 2.
Treatment characteristics
| Diphenhydramine | Cetirizine | |||
|---|---|---|---|---|
| Treatment 1 n = 13 |
Treatment 2 n = 11 |
Treatment 1 n = 14 |
Treatment 2 n = 13 |
|
| Dose of dexamethasone (n (%)) | ||||
| 10 mg | 8 (62) | 7 (64) | 11 (79) | 10 (77) |
| 20 mg | 5 (38) | 3 (27) | 3 (21) | 3 (23) |
| Other | 0 | 1 (9) a | 0 | 0 |
| H2 antihistamine (n (%)) | ||||
| Ranitidine 50 mg | 7 (54) | 3 (27) | 4 (29) | 5 (38) |
| Famotidine 20 mg | 6 (46) | 8 (73) | 10 (71) | 8 (62) |
| Time between end of H1 antihistamine administration and start of paclitaxel infusion in min (median (IQR)) b | 55 (15) | 58 (6) | 70 (18) | 71 (27) |
| Fasting 2 h before cetirizine administration (n (%)) | 14 (100) | 12 (92) | ||
| Fasting within 30 min of cetirizine administration (n (%)) | 13 (100) c | 11 (100) d | ||
| Duration of paclitaxel infusion in min (median (IQR)) e, f | ||||
| 45–80 mg/m2 | 82 (8) | 85 (9.5) | 85 (4) | 85 (10) |
| 175 mg/m2 | 195 (10) | 194 (10) | 195 (9.5) | 195 (8.5) |
a The participant received a 5-mg dose due to known adverse effects to corticosteroids
b The expected times were 30 min for diphenhydramine and 45 min for cetirizine
c One missing data (n = 13)
d Two missing data (n = 11)
e The expected times according to local institutional chemotherapy infusion protocols were 60 min for 45–80 mg/m2 and 180 min for 175 mg/m2
f Paclitaxel infusion rates are presented in Online Resource 2